Dr Robert G Feldman, MB, BS, PhD

Dr Andy Herbert, BSc, PhD

Here's what our clients say

”Rob was integral to the success of Tautoko Technology moving from an academic research project to a startup. Having a background in medicine, venture capital and startups gives Rob a holistic view of what it takes to be successful in the medtech space. Stepping into the commercial space is a big change, and with Rob's advice and experience behind us we have been able to move quickly and with confidence in building the business.”

-Dr  Jake Campbell, CEO Tautoko Technology

”The Commercial, Innovation, and Development team at the Garvan Institute had the privilege of collaborating with Robert on several projects focused on the commercial evaluation of our IP portfolio. These projects involved a review of assets such as IVDs, biomarkers, and early-stage stratification tools. Robert’s role demanded strategic insight, expert market analysis, and commercial acumen to provide clear guidance on the optimal approach for managing these assets.

Robert demonstrated exceptional efficiency and cost-effectiveness throughout the project. His guidance was not only clear and direct but also practical and insightful, ensuring that our decision-making was well-informed and aligned with our goals.

Beyond his professional acumen, Robert was an absolute pleasure to work with - approachable, reliable, highly experience and highly capable. His wealth of experience was evident in every interaction, and his contributions significantly benefited the Garvan Institute.

We highly recommend Robert to anyone seeking expert commercial insights and strategic guidance for navigating complex biotech and medtech IP and market challenges.”

- Dr Rachel Jaros, Commercialisation Manager, Garvan Institute

”Dr Andy Herbert provided services to Ferrier Research Institute’s Chemical and Synthetic Biology team at Victoria University of Wellington via Wellington UniVentures for the MBIE Endeavour-funded Fungal Factories project. Andy was engaged for technical advice for our fermentation optimisation and scale-up activities. His support for the project was invaluable and resulted in the efficient achievement of positive results, substantial transfer of skill to members of the Ferrier Research Institute team, and substantial savings in time and technical effort. Bringing a wealth of industry knowledge and technical expertise, Andy was an essential voice in technical planning meetings where he continually brought us back to the important questions and made pragmatic and informed suggestions about how these questions could be answered in the most efficient way possible. His support for the Fungal Factories project has been a positive force in the successful spinning out from Ferrier the synthetic biology company Bontia Bio Limited of which I am a founder and the CEO. Andy also provided extensive techno-economic models for industrial production of our products, ensuring that Bontia’s technology is fit-for-purpose in a commercial environment. I look forward to continuing to work with Andy in the future and can’t recommend him highly enough.”

-Dr Matt Nicholson, Founder and CEO, Bontia Bio Limited

”Dr Andy Herbert came on board as the Technical Director for Humble Bee Bio at a critical time for the company. Under his guidance, we made technical breakthroughs in the manufacturing and purifying of our protein. Our R&D staff blossomed under his calm and wise guidance. His expertise in biomanufacturing allowed us to make plans we could critically evaluate and the thorough and straightforward nature of his thinking and communication was greatly valued by the Board and myself as we made strategic decisions. I highly recommend Andy for early-stage life science companies and hope to work with him again.”

-Veronica Harwood-Stevenson, CEO, Humble Bee Bio

”Dr Robert Feldman was involved with the Science for Technological Innovation (SfTI) National Science Challenge of which I was Director. We engaged him to be an Impact Adviser for one of our early career researcher teams. Robert’s extensive background in human life sciences commercialisation made him the ideal fit for championing and guiding this team. I was impressed with how well-connected Robert was in the health/medtech ecosystem – very well known and respected – and an ideal calming and pragmatic foil for our enthusiastic but inexperienced entrepreneurial team.”

-Professor Emeritus Sally Davenport, MNZM MInstD, Wellington School of Business and Government